Akebia Therapeutics Inc (NASDAQ: AKBA) kicked off on Friday, down -5.76% from the previous trading day, before settling in for the closing price of $1.91. Over the past 52 weeks, AKBA has traded in a range of $0.80-$2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -8.86% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -9.12%. With a float of $209.46 million, this company’s outstanding shares have now reached $211.54 million.
In an organization with 167 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 4.00%, while institutional ownership is 28.71%. The most recent insider transaction that took place on Feb 03 ’25, was worth 302,925. In this transaction CEO and President of this company sold 144,250 shares at a rate of $2.10, taking the stock ownership to the 2,604,330 shares. Before that another transaction happened on Feb 03 ’25, when Company’s SVP, Chief Medical Officer sold 50,506 for $2.10, making the entire transaction worth $106,063. This insider now owns 816,234 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -9.12% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.16 million. That was inferior than the volume of 2.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.77%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 47.86%, which indicates a significant increase from 4.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.15% in the past 14 days, which was lower than the 58.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0172, while its 200-day Moving Average is $1.5487. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $1.9000. Second resistance stands at $2.0000. The third major resistance level sits at $2.0600. If the price goes on to break the first support level at $1.7400, it is likely to go to the next support level at $1.6800. The third support level lies at $1.5800 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 392.73 million has total of 218,181K Shares Outstanding. Its annual sales at the moment are 194,620 K in contrast with the sum of -51,930 K annual income. Company’s last quarter sales were recorded 37,430 K and last quarter income was -20,040 K.
